Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 29, 2025

Peter Schiff says 'biggest victims of inflation' will be ‘killed’ if they hold this investment. How to prepare for 2026

View original at finance.yahoo.com
Peter Schiff says 'biggest victims of inflation' will be ‘killed’ if they hold this investment. How to prepare for 2026 Gage Skidmore / Wikimedia Commons Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Morgan Stanley's suggested 20% allocation to gold is not chump change and could mark the start of a major shift as a huge wave of Wall Street money flows out of bonds and into gold

    80% confidence
  • Gold is now the anti-fragile asset to own, rather than Treasuries. High-quality equities and gold are the best hedges.

    80% confidence
  • Expects strong ETF inflows and continued central bank buying of gold

    80% confidence
  • Bonds are clearly the biggest victims of inflation. If you own bonds, inflation kills you. There is no hedge.

    80% confidence
  • Stocks can also be viewed as an inflation hedge, although not all stocks are the same in that respect

    80% confidence
  • For most people, the best thing to do is own the S&P 500 index fund

    80% confidence
  • The traditional 60/40 portfolio formula no longer holds up due to inflation

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com
Peter Schiff says 'biggest victims of inflation' will be ‘killed’ if they hold this investment. How to prepare for 2026 — Source | Via News | Finance Via News